CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seventh Sense Biosystems, a privately held medical device company developing integrated blood micro-collection and analysis platforms, announced today that it has initiated a registration trial for its painless TAP™ (Touch Activated Phlebotomy) blood collection device. The company expects to file for marketing authorization in the United States and in the European Union in the second quarter, and anticipates receiving its E.U. CE Mark and U.S. regulatory approval later this year.
